Akums Launches World's First Lasmiditan Dispersible Tablets for Acute Migraine Treatment
核心洞察
Akums Drugs & Pharmaceuticals has launched the world's first DCGI-approved Lasmiditan dispersible tablets, introducing a patient-friendly formulation for acute migraine (搜索) relief.
The dispersible formulation addresses practical challenges during migraine (搜索) attacks, including nausea and difficulty swallowing, by dissolving quickly in water for easier administration.
Lasmiditan functions as a highly selective serotonin 5-HT1F receptor (搜索) agonist with binding affinity more than 440 times higher than for 5-HT1B/1D receptors.
Akums Drugs & Pharmaceuticals Ltd (搜索). has announced the launch of the world's first Lasmiditan dispersible tablets, marking a significant advancement in acute migraine (搜索) treatment. The DCGI-approved formulation introduces a patient-friendly approach designed to provide faster and more convenient relief during sudden migraine attacks.
Addressing Global Migraine Burden
Headache disorders (搜索) remain among the most common neurological conditions worldwide, yet they often remain under-recognised and inadequately treated. Migraine (搜索), in particular, is a debilitating neurovascular disorder characterised by recurrent episodes of throbbing, often one-sided headaches. These episodes frequently occur alongside symptoms such as nausea, vomiting, and sensitivity to light and sound.
Globally, more than one billion people live with migraine (搜索), making it one of the most prevalent neurological conditions. Consequently, improving access to effective and easy-to-administer treatments has become a critical priority in migraine care.
Patient-Centric Formulation Design
The new dispersible tablet formulation addresses practical challenges patients face during migraine (搜索) attacks. Migraine episodes often involve nausea, gastric stasis, vomiting, and difficulty swallowing, which can make conventional tablets difficult to take. The dispersible formulation can be mixed in a small amount of water, allowing patients to consume the medication more comfortably during an attack.
This design improves treatment accessibility and patient compliance, particularly when symptoms make swallowing difficult. The formulation incorporates a dual disintegration mechanism involving swelling and effervescence, enabling rapid dispersion of the tablet and facilitating faster therapeutic action during acute migraine (搜索) episodes.
Advanced Technology for Enhanced Patient Experience
Akums has developed advanced taste-masking technology to counter the intensely bitter taste of Lasmiditan. This technological improvement makes the formulation more palatable, making it easier for patients to take the medication during severe attacks. Together, these technological improvements enhance the overall treatment experience and support better adherence to therapy.
Targeted Mechanism of Action
Lasmiditan belongs to the 'ditans' class of anti-migraine (搜索) medications and functions as a highly selective serotonin 5-HT1F receptor (搜索) agonist. The drug demonstrates a binding affinity that is more than 440 times higher for the 5-HT1F receptor compared to the 5-HT1B/1D receptors.
Because of this selectivity, Lasmiditan acts directly on sensory neurons involved in migraine (搜索) pathways. Clinicians often describe it as a neurally active anti-migraine agent. The drug is indicated for the acute treatment of migraine with or without aura in adults, although it is not intended for preventive therapy.
Industry Leadership and Innovation
Commenting on the development, Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd (搜索)., said: "Anyone who has experienced a migraine (搜索) understands how suddenly and intensely it can disrupt everyday life. In those moments, patients need relief that is not only effective but also convenient to take. With the world's first Lasmiditan dispersible tablets, we wanted to create a solution that addresses real patient challenges."
Jain emphasized the practical benefits: "The formulation disperses quickly in water, which is especially helpful during attacks when nausea or difficulty swallowing makes conventional tablets difficult to use. At Akums, we remain committed to developing thoughtful pharmaceutical innovations that combine strong science with practical patient needs, ultimately improving the treatment experience."
By combining Lasmiditan's targeted mechanism with a dispersible and easy-to-administer dosage form, Akums has introduced a next-generation option for managing acute migraine (搜索) attacks. The formulation allows quick administration, rapid onset of action, and improved bioavailability, while eliminating the need to swallow conventional tablets. This approach is particularly beneficial for patients who experience nausea or vomiting during migraine episodes, enabling them to take medication more easily at the onset of symptoms.